Skip to content Skip to footer
Subscribe Now
Top 20 Biopharma 2025
TOP 20

Top 20 Biopharma Companies of 2025 

Shots:  Driven by innovation and a steadfast commitment to advancing cutting-edge therapies, the biopharma industry experienced robust growth in 2024, marked by significant revenue milestones  With a projected compound annual growth rate (CAGR) of 12.87%, the global biopharma market is expected to reach $1.41 trillion by 2032. In 2024, Pfizer led the industry with total…
April 24, 2025

Read more

Viewpoints_Chris Gasink
VIEWPOINTS

Unlocking Approval: Chris Gasink from Johnson & Johnson in an Enlightening Conversation with PharmaShots

Shots: Johnson & Johnson’s (J&J) Tremfya recently received its third approval from the US FDA, supported by the pivotal QUASAR study, which demonstrated significant remission after one year of treatment in adults with moderately to severely active ulcerative colitis Tremfya is a dual-binding monoclonal antibody targeting interleukin 23 (IL-23), a cytokine responsible for inflammation At…
February 3, 2025

Read more

VIEWPOINTS_Jennifer Davidson_2023
VIEWPOINTS

Jennifer Davidson Highlights the Data from the Phase 3 QUASAR Induction Study 1

Shots:  Jennifer Davidson, VP, of Medical Affairs Immunology, Johnson & Johnson Innovative Medicine shares insights from the data of the Phase III QUASAR induction study presented at the DDW'23  P-III QUASAR induction study 1 demonstrated positive results in patients who received TREMFYA 200 mg vs Placebo, with most of the patients achieving remission at week…
November 13, 2023

Read more

VIEWPOINTS_Jennifer Davidson1_2023
VIEWPOINTS

Jennifer Davidson, VP, Medical Affairs, Immunology at the Janssen Pharmaceutical Shares Insights from QUASAR Induction Study-I Evaluating Tremfya

Shots: Jennifer talked about the results from QUASAR Induction Study-I evaluating Tremfya in adults with moderately to severely active ulcerative colitis presented at the 2022 American College of Gastroenterology Annual Meeting He also gave an overview of Trefmya focusing on major advances. He also spoke about the epidemiology and etiology of Ulcerative Colitis The interview…
April 6, 2023

Read more

PharmaShots Interview Daphne Chan, Head of Dermatology Medical Affairs at Janssen Shares Insights on Clinical Study in Dermatology
VIEWPOINTS

PharmaShots Interview: Daphne Chan, Head of Dermatology Medical Affairs at Janssen Shares Insights on Clinical Study in Dermatology

Shots: Daphne talked about the P-III study evaluating the safety and efficacy of Tremfya in people of color living with moderate to severe plaque psoriasis Daphne also spoke about how this clinical study will contribute to fill the gaps in care of people who are devoid of treatment due to racial and ethnic variations The…
July 26, 2022

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]